Differences in CSF Biomarkers Profile of Patients with Parkinson’s Disease Treated with MAO-B Inhibitors in Add-On

Differences in CSF Biomarkers Profile of Patients with Parkinson’s Disease Treated with MAO-B Inhibitors in Add-On
J Integr Neurosci. 2022 Oct 8;21(6):165. doi: 10.31083/j.jin2106165.ABSTRACTBACKGROUND: Monoamine oxidase type B inhibitors (iMAO-Bs) are a class of largely-used antiparkinsonian agents that, based on experimental evidence, are supposed to exert different degrees of neuroprotection in Parkinson's disease (PD). However, clinical proofs on this regard are very scarce. Since cerebrospinal fluid (CSF) reflects pathological changes occurring at brain level, we examined ... read more
Source: PubMedPublished on 2022-11-25By Henri Zenuni